Top > Search of International Patents > AQUAPORIN 4 FUNCTION PROMOTER AND PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS

AQUAPORIN 4 FUNCTION PROMOTER AND PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS

Foreign code F170009244
File No. (S2016-0325-N0)
Posted date Sep 21, 2017
Country WIPO
International application number 2017JP008485
International publication number WO 2017150704
Date of international filing Mar 3, 2017
Date of international publication Sep 8, 2017
Priority data
  • P2016-042766 (Mar 4, 2016) JP
Title AQUAPORIN 4 FUNCTION PROMOTER AND PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS
Abstract An aquaporin 4 function promoter contains, as an active ingredient, a compound represented by general formula (1) or (2) or a pharmacologically acceptable salt thereof. (In the formulas, n11 is an integer of 1-10. R21 is a C1-10 alkyl group, alicyclic heterocyclic group, aromatic hydrocarbon group, or aromatic heterocyclic group.)
Scope of claims [claim1]
1. The below-mentioned general formula the chemical compound which is displayed with (1), or that the akuaporin 4 functional accelerator which features that it contains the salt which can be allowed pharmacy as the active ingredient.
(In formula, n (11) it is integer of the 1-10.)
[claim2]
2. The aforementioned chemical compound 2 - in the claim 1 which is guanidinoacetic - 1 - ethane sulfonic acid or 2 the akuaporin 4 functional accelerator of statement.
[claim3]
3. Either of the claim 1-3 the medicine composition for the nervous disease which features that inside the akuaporin 4 functional accelerator of statement, and the carrier and the diluent which can be allowed pharmacy at least each of them is included in one section.
[claim4]
4. In each case the aforementioned nervous disease is chosen from the Alzheimer's disease, the brain blockage and the group which consists of the encephaloma it is one, in claim 4 the medicine composition for the nervous disease of statement.
[claim5]
5. The below-mentioned general formula the chemical compound which is displayed with (2), or that the akuaporin 4 functional accelerator which features that it contains the salt which can be allowed pharmacy as the active ingredient.
(In formula, R (21) the alkyl group of the carbon count 1-10, it is the fat cyclic complex ring basis, the aromatic hydrocarbon radical or the aromatic complex ring basis.)
[claim6]
6. The description above R (21) the methyl group, the ethyl group, the n-puropiru basis, the i-puropiru basis, the n-buchiru basis, the i-buchiru basis, the sec-buchiru basis, the n-penchiru basis, the i-penchiru basis, the n-hekishiru basis, the shikuropuropiru basis, the shikurobuchiru basis, the cyclopentyl basis and the shikurohekishiru basis, 2 - the pirorijiniru basis, 3 - the pirorijiniru basis, 2 - the tetorahidorohuraniru basis, 3 - the tetorahidorohuraniru basis, 2 - the pyro rill basis, 3 - the pyro rill basis, 2 - the huraniru basis, or 3 - is the huraniru basis, in claim 6 the akuaporin 4 functional accelerator of statement.
[claim7]
7. The aforementioned chemical compound 2 - phenyl sulfonic amide - 3 - in the claim 6 which is benzyl oxy pyrimidine or 7 the akuaporin 4 functional accelerator of statement.
[claim8]
8. Either of the claim 6-8 the medicine composition for the nervous disease which features that inside the akuaporin 4 functional accelerator of statement, and the carrier and the diluent which can be allowed pharmacy at least each of them is included in one section.
[claim9]
9. In each case the aforementioned nervous disease is chosen from the Alzheimer's disease, the brain blockage and the group which consists of the encephaloma it is one, in claim 9 the medicine composition for the nervous disease of statement.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • NAKADA TSUTOMU
  • HUBER VINCENT
  • IGARASHI HIRONAKA
  • SUZUKI YUJI
  • KWEE INGRID
IPC(International Patent Classification)
Specified countries (WO2017150704)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close